Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism.

Brix, Thomas H; Hegedüs, Laszlo; Hallas, Jesper; Lund, Lars C

Brix, Thomas H; Hegedüs, Laszlo; Hallas, Jesper; Lund, Lars C.

Brix TH; Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark. Electronic address: thomas.brix@rsyd.dk.
Hegedüs L; Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark.
Hallas J; Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
Lund LC; Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.

Lancet Diabetes Endocrinol ; 9(4): 197-199, 2021 04.

Article in English | MEDLINE | ID: covidwho-1142354

Subject(s)

COVID-19/diagnosis; COVID-19/epidemiology; Hyperthyroidism/epidemiology; Hypothyroidism/epidemiology; Adult; Aged; Aged, 80 and over; COVID-19/pathology; COVID-19/therapy; Comorbidity; Disease Progression; Female; Hospital Mortality; Humans; Hyperthyroidism/therapy; Hypothyroidism/therapy; Male; Middle Aged; Mortality; Patient Outcome Assessment; Prognosis; Propensity Score; Risk Assessment; Risk Factors; SARS-CoV-2/pathogenicity; Severity of Illness Index

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hyperthyroidism / Hypothyroidism Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Lancet Diabetes Endocrinol Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google